PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis

被引:208
作者
Bykov, VJN
Zache, N
Stridh, H
Westman, J
Bergman, J
Selivanova, G
Wiman, KG [1 ]
机构
[1] CCK, Dept Oncol Pathol, Stockholm, Sweden
[2] Aprea AB, Stockholm, Sweden
[3] Novum, Dept Biosci, Stockholm, Sweden
[4] Karolinska Inst, Ctr Microbiol & Tumor Biol, Stockholm, Sweden
关键词
p53; mutation; cancer therapy; chemotherapeutic drugs; PRIMA-1; synergy;
D O I
10.1038/sj.onc.1208419
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutant p53-carrying tumors are often more resistant to chemotherapeutical drugs. We demonstrate here that the mutant p53-reactivating compound PRIMA-1(MET) acts synergistically with several chemotherapeutic drugs to inhibit tumor cell growth. Combined treatment with cisplatin and PRIMA-1(MET) resulted in a synergistic induction of tumor cell apoptosis and inhibition of human tumor xenograft growth in vivo in SCID mice. The induction of mutant p53 levels by chemotherapeutic drugs is likely to increase the sensitivity of tumor cells to PRIMA-1(MET). Thus, the combination of PRIMA-1(MET) with currently used chemotherapeutic drugs may represent a novel and more efficient therapeutic strategy for treatment of mutant p53-carrying tumors.
引用
收藏
页码:3484 / 3491
页数:8
相关论文
共 24 条
[1]   COMPLETE SEQUENCING OF THE P53 GENE PROVIDES PROGNOSTIC INFORMATION IN BREAST-CANCER PATIENTS, PARTICULARLY IN RELATION TO ADJUVANT SYSTEMIC THERAPY AND RADIOTHERAPY [J].
BERGH, J ;
NORBERG, T ;
SJOGREN, S ;
LINDGREN, A ;
HOLMBERG, L .
NATURE MEDICINE, 1995, 1 (10) :1029-1034
[2]   TP53 and breast cancer [J].
Borresen-Dale, AL .
HUMAN MUTATION, 2003, 21 (03) :292-300
[3]   Disruption of p53 in human cancer cells alters the responses to therapeutic agents [J].
Bunz, F ;
Hwang, PM ;
Torrance, C ;
Waldman, T ;
Zhang, YG ;
Dillehay, L ;
Williams, J ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) :263-269
[4]   Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database [J].
Bykov, VJN ;
Issaeva, N ;
Selivanova, G ;
Wiman, KG .
CARCINOGENESIS, 2002, 23 (12) :2011-2018
[5]   Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound [J].
Bykov, VJN ;
Issaeva, N ;
Shilov, A ;
Hultcrantz, M ;
Pugacheva, E ;
Chumakov, P ;
Bergman, J ;
Wiman, KG ;
Selivanova, G .
NATURE MEDICINE, 2002, 8 (03) :282-288
[6]   The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth [J].
Cadwell, C ;
Zambetti, GP .
GENE, 2001, 277 (1-2) :15-30
[7]  
Campling Barbara G, 2003, Methods Mol Med, V75, P53
[8]   Pharmacological rescue of mutant p53 conformation and function [J].
Foster, BA ;
Coffey, HA ;
Morin, MJ ;
Rastinejad, F .
SCIENCE, 1999, 286 (5449) :2507-2510
[9]   Chemosensitivity linked to p73 function [J].
Irwin, MS ;
Kondo, K ;
Marin, MC ;
Cheng, LS ;
Hahn, WC ;
Kaelin, WG .
CANCER CELL, 2003, 3 (04) :403-410
[10]   Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide [J].
Issaeva, N ;
Friedler, A ;
Bozko, P ;
Wiman, KG ;
Fersht, AR ;
Selivanova, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (23) :13303-13307